Nsclc ציבורי
[search 0]
עוד

Download the App!

show episodes
 
Not only is lung cancer the leading cause of cancer deaths among females and males, but it’s also the most common type of cancer. Despite its high prevalence and mortality rates, communicative care between non-small cell lung cancer (NSCLC) patients and their providers is still unfortunately lacking. In an effort to both address and resolve this disparity, Closing the Gaps in NSCLC will focus on the latest guidelines and the current therapeutic landscape within NSCLC. This non-certified educ ...
 
Loading …
show series
 
Host: Paul Doghramji, MD Guest: Tony Y. Hu, PhD One of the biggest blindspots for those who care for patients with lung cancer is not knowing whose disease is going to metastasize quickly and who, by extension, would benefit from the most aggressive treatments up front. But the entrance of better detection methods, such as biomarkers and assay test…
 
Host: Paul Doghramji, MD Guest: Tony Y. Hu, PhD Since treatment outcomes vary greatly between lung cancer patients—even among those who are diagnosed at the same stages of disease—much research has been devoted to finding biomarkers that identify patients who are most likely to develop metastatic disease. Here to walk us through a promising line of…
 
Guest: Amit Bobby Mahajan, MD, FCCP, DAABIP Lung cancer is known to be the deadliest and second most common cancer in men and women. Although there currently isn’t a cure, the last decade has shown great improvements and hope for the treatment of non-small cell lung cancer, as Dr. Bobby Mahajan explains.…
 
Host: Paul P. Doghramji, MD, FAAFP Guest: Edward S. Kim, MD Thanks to recent research, we can now use a non-small cell cancer patient’s cancer type and genomic makeup to create targeted treatment plans. Joining Dr. Paul Doghramji to share what that approach looks like in practice is Dr. Edward Kim, the Chair of Solid Tumor Oncology and Investigatio…
 
Guest: Edward S. Kim, MD When looking at the non-small cell lung cancer landscape, we’re now seeing the emergence of several genetic markers that may have therapies linked to them, and one of those markers is the RET fusion that exists. Join Dr. Edward Kim as he gets us caught up on the investigational therapies targeting RET-mutated non-small cell…
 
Guest: Michael R. Shafique, MD The therapies that have been approved for non-small cell lung cancer stimulate the immune system to attack cancer cells… But what happens when they do too good a job of that and stimulate the immune system to inflame other parts of the body as well? Dr. Michael Shafique from the Moffitt Cancer Center breaks down the m…
 
Guest: Michael R. Shafique, MD After many decades of trying to improve the outcomes of patients with advanced non-small cell lung cancer, we may finally have the therapeutic approach that achieves that goal: maintenance therapy. Join Dr. Michael Shafique, an Assistant Professor of Thoracic Oncology at the Moffitt Cancer Center, as he reviews the da…
 
Guest: Deepa Rangachari, MD Communication is the key to guiding patients with non-small cell lung cancer through testing and treatment, but what exactly does that look like? Dr. Deepa Rangachari, an oncologist at the Beth Israel Deaconess Medical Center, shares strategies to help patients understand these processes and set realistic expectations.…
 
Guest: Deepa Rangachari, MD With newly approved therapies on the rise, the way we treat non-small cell lung cancer patients with a RET gene rearrangement may be evolving. That’s why it’s so important to test for RET mutations in patients with non-small cell lung cancer, as oncologist Dr. Deepa Rangachari explains.…
 
Guest: Deepa Rangachari, MD Living with non-small cell lung cancer means living with a daily burden of symptoms like fatigue, decreased appetite, and shortness of breath. Dr. Deepa Rangachari, an oncologist at Harvard’s Beth Israel Deaconess Medical Center, expresses the importance of finding therapeutic strategies to help patients manage symptoms.…
 
Host: Jennifer Caudle, DO Guest: Deepa Rangachari, MD Survival rates for patients with non-small cell lung cancer have notably improved thanks to the development of targeted therapies and immunotherapies. With these recent advancements on the forefront, Dr. Deepa Rangachari joins Dr. Jennifer Caudle to discuss the KEYNOTE-189 study and how it could…
 
Guest: Jacob Sands, MD Take a deep dive into the data from a recent clinical trial exploring next generation sequencing in lung squamous cell carcinoma with Dr. Jacob Sands, a thoracic medical oncologist at the Dana-Farber Cancer Institute and an Instructor of Medicine at Harvard Medical School.
 
Guest: Jacob Sands, MD Although a lung cancer diagnosis can take a heavy toll on a patient’s mental and emotional well-being, there are counseling strategies you can use to better communicate with your patients and to ease their fears. Here to share the strategies he uses to help his patients cope with a lung cancer diagnosis is Dr. Jacob Sands, a …
 
Host: Jennifer Caudle, DO Guest: Michael R. Shafique, MD Although only a small percentage of patients with non-small cell lung cancer have a genetic mutation involving the RET gene, it’s still essential that we know how this specific mutation impacts our diagnostic and treatment approach. That’s why we’re taking a look at this through the lens of a…
 
Loading …

מדריך עזר מהיר

זכויות יוצרים 2021 | מפת אתר | מדיניות פרטיות | תנאי השירות
Google login Twitter login Classic login